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Abstract
The incidence of double cancer of the esophagus and breast is rare, and axillary lymph node metastasis (ALM)
in esophageal cancer is also very rare. We report a case of advanced esophageal cancer with left ALM and
synchronous right breast cancer. A 64-year-old woman was admitted to our hospital with dysphagia. The clinical
diagnosis was esophageal cancer (T3N0M1 stage IV) and right breast cancer (T1cN0M0 stage I). She was initially
treated with triple chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. The primary lesion in the esophagus
achieved almost complete response as assessed by esophageal endoscopy. A computed tomography scan showed
that the left ALM reduced in size and that stable disease was achieved for the right breast cancer. She underwent
partial mastectomy of the right breast and bilateral axillary lymph node dissection. The histopathological diagnosis
of the breast cancer was T1cN1M0 stage IIA. The lymph nodes from the left axilla contained metastatic cells from
the squamous cell carcinoma of the esophagus. Complete response was achieved for the primary lesion in the
esophagus following chemoradiotherapy (CRT), and the patient has been relapse free 2 years after treatment. Thus,
we report the successful treatment of synchronous double cancers of the esophagus with left ALM and right breast
by combination therapy with chemotherapy, CRT, and surgery.
Keywords: Esophageal cancer; Synchronous double cancer; Axillary lymph node metastasis; DCF therapy
Background
The incidence of multiple cancers of the esophagus and
other organs reportedly ranges from 9.5 to 20.7 % [1].
Head and neck squamous cell carcinoma and gastric
adenocarcinoma are most frequently observed as mul-
tiple primary cancers of other organs in patients with
esophageal cancer [2, 3]. In cases of synchronous mul-
tiple cancers with distant metastasis (liver, pulmonary,
and/or distant lymph node metastasis), it is sometimes
difficult to diagnose the primary site of the distant metas-
tasis and to decide on the order of priority of treatment
among the synchronous cancers. The incidence of double
cancer of the esophagus and breast is rare [4], and axillary
lymph node metastasis (ALM) from esophageal cancer [5]
and contralateral ALM from breast cancer [6, 7] are also
very rare. Here we report a case of synchronous double
cancers of the esophagus with left ALM and right breast.
Case presentation
A 64-year-old woman was admitted to our hospital with
dysphagia in November 2012. Esophagogastroscopy re-
vealed an ulcerated circumferential mass in the middle
thoracic esophagus (Fig. 1a), and histopathological examin-
ation of the biopsy showed squamous cell carcinoma
(Fig. 1b). Computed tomography (CT) revealed an esopha-
geal tumor, right breast tumor, and two enlarged axillary
lymph nodes on the left side. However, invasion of the
esophageal tumor to adjacent organs was not observed
(Fig. 2a). The breast tumor was 16 mm in diameter and
was located at the lateral area of the right breast tissue
(Fig. 2f). Two enlarged lymph nodes were observed in the
left axillary space (13.8 and 14.7 mm in the short-axis
plane) (Fig. 2d). All the other detectable lymph nodes (left
supraclavicular node, right recurrent nerve node, and the
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node in the lesser curvature of the stomach) were less than
7.0 mm in size (Fig. 2b, c, e).
Fluorine-18 (18F) fluorodeoxyglucose (FDG) positron
emission tomography–computed tomography (PET–CT)
scan showed hypermetabolic lesions in the thoracic
esophagus [standardized uptake value (SUV) max of 12.6],
right breast (SUV max of 2.0), left axillary lymph nodes
(SUV max of 3.6; Fig. 3a, c), and right supraclavicular
region (SUV max of 3.4), which was not detected in the
CT scan. FDG accumulation was not observed in the
other nodes, including the lymph nodes detected in the
chest and abdominal CT. Ultrasonographic examination
revealed a solid mass measuring 1.0 cm × 0.9 cm in the
upper outer quadrant of the right breast. Core needle
biopsy from the tumor in the right breast revealed a scir-
rhous carcinoma, a subtype of invasive ductal carcinoma,
that was positive for estrogen receptors (ERs) but negative
for progesterone receptors (PgRs) and HER2/Neu. Fine-
needle aspiration cytology from the left ALM did not
provide definitive diagnosis of cancer cells. The clinical
diagnosis was esophageal cancer (T3N0M1 stage IV
according to the 7th edition of the Union for International
Cancer Control classification) and synchronous right
breast cancer (T1cN0M0 stage I). She was treated initially
by triple chemotherapy with docetaxel, cisplatin, and 5-
fluorouracil (DCF) as an induction chemotherapy for the
esophageal cancer, with four courses over 4 weeks of
docetaxel (60 mg/m2 on day 1), cisplatin (80 mg/m2 on
day 1), and 5-fluorouracil (800 mg/m2 on days 1–5).
Grade 3 leukopenia and neutropenia (according to the
Common Terminology Criteria for Adverse Events
Version 4.0) were observed during each course, but all
other events were mild in severity. The therapeutic effect
of the chemotherapy was evaluated after the four
courses of DCF in April 2013. The primary lesion in the
esophagus was markedly flattened, and only shallow
ulcer scarring was observed by esophageal endoscopy
(Fig. 1c). The biopsy from the ulcerative lesion revealed
no malignancy. The chest CT scan showed that the left
ALM and right breast cancer had both reduced in size
(Fig. 4d, f ). The PET–CT scan showed disappearance of
the FDG accumulation in the primary tumor and left ALM
(Fig. 3b, d) but no changes in the right breast cancer (SUV
max 2.0). She underwent partial mastectomy of the right
breast and bilateral axillary lymph node dissection. The
histopathological diagnosis was as follows: invasive ductal
carcinoma, scirrhous carcinoma, nuclear grade 2, positive
for lymph node metastasis (1/16), ER: positive, PgR: nega-
tive, HER2/Neu: negative (1+ on immunohistochemistry),
Ki67: <5, phenotype: luminal A, pTNM stage: T1cN1M0
stage IIA. One sentinel lymph node in the right axilla con-
tained metastatic cells from the breast cancer (Fig. 5c). The
chemotherapy was not histologically efficacious for either
the right breast cancer or the right axillary lymph node
Fig. 1 Esophagogastroscopy findings of the esophagus and pathological findings for the esophageal cancer. a Esophagogastroscopy revealed
an ulcerated circumferential mass in the middle thoracic esophagus. b Pathological examination of the biopsy from the esophagus showed
squamous cell carcinoma (×100 magnification). c Esophagogastroscopy after four courses of chemotherapy with docetaxel, cisplatin, and
5-fluorouracil revealed that the lesion was markedly flattened and only the ulcer was left. d Esophagogastroscopy after chemoradiotherapy
revealing that the lesion had vanished and only a scar was left
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(grade 0 according to The General Rules for Clinical and
Pathological Recording of Breast Cancer, 17th edition) [8].
These findings suggest that DCF was not effective for the
treatment of breast cancer in this case. In contrast, only
one of the nine dissected lymph nodes from the left axilla
contained metastatic cells from the squamous cell carcin-
oma of the esophagus (Fig. 5d). DCF treatment was shown
to be slightly effective by histological evaluation of the left
axillary metastatic lymph node (grade 1a according to the
Japanese Classification of Esophageal Cancer, 10th edition)
[9]. There were no complications associated with the
chemotherapy during or after surgery. The patient was dis-
charged from hospital 5 days after the surgery with no
complications.
One month after the operation, she underwent chemo-
radiotherapy (CRT) for the esophageal cancer. The CRT
regimen comprised cisplatin (70 mg/m2) on days 1 and
29, 5-fluorouracil (700 mg/m2) on days 1–4 and 29–32,
and radiotherapy involving a total of 60 Gy in 30 frac-
tions. The target fields of radiotherapy for esophageal can-
cer were the main tumor and regional lymph nodes,
including the mediastinum and left supraclavicular nodes,
and involved a total of 60 Gy. During chemotherapy, me-
tastases were not detected in the right supraclavicular and
abdominal regions; thus, these regions were excluded
from the radiation field to preserve the bloodstream in the
cervical esophagus and trachea, in consideration of salvage
esophagectomy when recurrence of esophageal tumor
would be observed in the future. Prophylactic irradiation
after lymphadenectomy of the left axillary space was also
simultaneously performed with a total dose of 50.4 Gy.
Because of the prognosis of advanced esophageal cancer
and the effectiveness of local control by an aromatase in-
hibitor, we decided to omit radiation therapy to conserve
the breast.
Evaluation of the primary lesion in the esophagus after
CRT using endoscopy revealed a complete response
(Fig. 1d), and the patient is still relapse free 2 years after
treatment. The patient was administered a common aro-
matase inhibitor, letrozole, as a hormonal therapy after
mastectomy.
Discussion
There have been few case reports of metastasis of the
breast cancer to the esophagus and vice versa [10, 11] or
metachronous esophageal cancer developing after radi-
ation therapy for primary breast cancer [12, 13]. How-
ever, synchronous double cancer of the esophagus and
Fig. 2 Chest and abdominal computed tomography at admission. a Wall thickening in the middle thoracic esophagus. b The left supraclavicular
lymph node (7.0 mm in the short-axis plane). c The right recurrent nerve lymph node (7.0 mm in the short-axis plane). d Lymph node metastases
in the left axillary space (13.8 and 14.7 mm in the short-axis plane). e Lymph node along the lesser curvature of the stomach (6.7 mm in the
short-axis plane). f Mass of the right breast (maximum diameter of 16 mm)
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breast is very rare, and only one case has been reported
to our knowledge [4]. Natugoe et al. [1] reported that
double cancer of the esophagus and breast was observed
in only one patient in 157 cases of multiple primary can-
cers with esophageal squamous cell carcinoma, including
synchronous and metachronous types. From the epi-
demiological perspective, the main reason for the low
frequency of multiple cancers of the esophagus and breast
is the gender difference for each cancer type. Esophageal
squamous cell carcinoma occurs about six times more
frequently in men than women [14], and the overwhelm-
ing majority of breast cancer occurs in women. Moreover,
cancers in the upper aerodigestive tract, such as the head
and neck, esophagus, stomach, and lung, may be com-
monly influenced by direct exposure of irritant substances
by tobacco smoking and alcohol consumption. Although
tobacco and alcohol are also risk factors for breast cancer,
these irritants may have less influence on the mechanism
of breast cancer development compared with that of the
aerodigestive tract.
In our present case, histological diagnosis of the left
ALM could not be obtained at the commencement of
treatment. Both the ALM from the esophageal cancer and
contralateral breast cancer were diagnosed as distant me-
tastases, which are usually treated as systemic diseases.
Incidences of contralateral ALM vary between 1.9 and 6 %
for all breast cancers [6]. Morcos et al. [7] reported 21
patients with contralateral ALM; this type of metastasis is
associated with tumors with aggressive pathological fea-
tures, including locally advanced cancer (cT3/cT4: 95 %,
stage III: 90 %), invasive ductal type (95 %), high grade
(grade 3 carcinomas: 81 %), lymphovascular invasion
(81 %), ER-receptor negativity (52 %), and HER2 overex-
pression (42 %). The breast cancer in our case was clinically
diagnosed as T1cN0M0 (stage I); thus, we considered the
left ALM to be a metastasis from the esophageal cancer.
Fig. 3 Positron emission tomography–computed tomography (PET–CT) findings. a PET–CT scan showing accumulation in the middle esophagus
(standardized uptake value [SUV] max of 12.6). b PET–CT scan after four courses of chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF)
showing the disappearance of the accumulation in the primary tumor. c PET–CT scan showing accumulation in the left axillary lymph node (SUV max
of 3.6). d PET–CT scan after four courses of DCF treatment showing the disappearance of the accumulation in the left axillary lymph node
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ALM from esophageal cancer is rare [5]. Komatsu
et al. reported four cases of ALM from esophageal can-
cer, and the incidence was 1.1 % in 361 esophageal can-
cer patients who underwent esophagectomy. In the
report, all four patients had left ALM with ipsilateral left
supraclavicular lymph node metastasis, and all ALMs
were recognized as recurrences after locoregional treat-
ment for esophageal cancer; two cases developed after
esophagectomy and the other two after CRT for the pri-
mary lesions. This is the first report of ALM synchron-
ously occurring with primary esophageal cancer. The
mechanisms underlying metastasis to the axillary lymph
nodes in esophageal cancer have not yet been elucidated.
However, the theory of retrograde spread from the supra-
clavicular lymph nodes to the axillary nodes has been pro-
posed in bronchogenic and lung carcinomas [15, 16].
Because all four cases of ALM reported by Komatsu et al.
[5] had supraclavicular lymph node metastasis, the au-
thors concluded that ALM from esophageal cancer could
also be caused by retrograde flow owing to lymphatic
blockade by the supraclavicular lymph node metastasis. In
our present case, however, supraclavicular lymph node
metastasis was not observed, although left ALMs were
revealed by the CT and PET–CT scans. Bourgeosis et al.
[17] reported the pattern and frequency of thoracic lymph
duct drainage routes by visualization of the supradiaph-
ragmatic lymph nodes using lymphoscintigraphy in 334
cases. In their results, supradiaphragmatic lymph nodes
associated with the thoracic duct were demonstrated in
43.2 % of cases, with 10 % in the mediastinum, 41 % in the
left supraclavicular/retroclavicular region, and 2.4 % in the
right supraclavicular/retroclavicular region. Interestingly,
in two cases (0.6 %), draining of the mediastinum and a
chain of lymph nodes toward the left axilla was demon-
strated without visualizing the supraclavicular nodes.
Therefore, it is possible that our present case had a direct
lymphoid route to the left axilla bypassing the left supra-
clavicular area.
Triplet chemotherapy with DCF has shown superiority
to combined cisplatin and 5-fluorouracil in terms of
overall survival for head and neck cancer as well as gas-
tric cancer [18–20]. Recently, DCF has also been re-
ported to be effective for esophageal cancer [21, 22],
with several reports demonstrating a 53.7–62.5 % re-
sponse rate of esophageal cancer to DCF; progressive
disease was observed in 0–1.9 % [21, 22], and thus, DCF
Fig. 4 Chest and abdominal computed tomography after four courses of chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. a The wall
thickening in the middle thoracic esophagus had almost disappeared. b The size of the left supraclavicular lymph node did not change (8.0 mm
in the short-axis plane). c The size of the right recurrent nerve lymph node had reduced (3.3 mm in the short-axis plane). d The size of the lymph
node metastases in the left axillary space had reduced (9.3 and 2.1 mm in the short-axis plane). e The size of the lymph node along the lesser
curvature of the stomach had reduced (5.7 mm in the short-axis plane). f The mass of the right breast had reduced in size (maximum diameter
of 13.6 mm)
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may be useful for neoadjuvant or induction therapy.
Each drug in DCF has been widely used in chemother-
apy for various cancers, and high efficacy of DCF has
been shown in various cancers regardless of histological
type, whether it is squamous cell carcinoma or adeno-
carcinoma. Therefore, DCF may be a suitable first-line
therapy for multiple primary cancers of the esophagus
and other organs with distant metastasis.
We selected induction DCF chemotherapy as the first-
line therapy for this case of systemic disease of esopha-
geal cancer. As the primary tumor size was markedly
reduced after four courses of DCF and new lesions were
not observed during approximately 5 months of chemo-
therapy, we assumed that this case of radical cure of
cancer was due to the relatively localized disease. It is
well known that the rate of radical cure from advanced
esophageal cancer by systemic chemotherapy alone is
quite low, and locoregional treatment is usually required
to cure these patients. Considering that the patient was
originally diagnosed with stage IV esophageal cancer
with distant metastasis, we considered that CRT was
preferable than surgery because of the concurrent use of
chemotherapy with cisplatin and 5-fluorouracil as sys-
temic therapy. We proposed both the treatments to the
patient, and she selected CRT. Two courses of combin-
ation chemotherapy with cisplatin and 5-fluorouracil are
usually used in standard CRT for esophageal cancer. To
prevent irreversible adverse events, such as neuropathy
and renal failure, due to the highly accumulative dose of
cisplatin, CRT was followed by four cycles of DCF in this
case. The total dose of cisplatin was 460 mg/m2, and no
adverse events have been observed to date.
Conclusions
Herein, we reported the successful treatment of synchron-
ous double cancers of the esophagus with left ALM and
right breast by combination therapy with chemotherapy,
CRT, and surgery.
Fig. 5 Macroscopic and microscopic findings of the resected specimen. a Surgical specimen of the right breast. b Pathological examination of a
specimen from the breast showed scirrhous carcinoma, a grade II invasive ductal carcinoma (×100 magnification). c Pathological examination of a
specimen from the right axillary lymph node showed metastatic cells from the invasive ductal carcinoma of the breast (×100 magnification).
d Pathological examination of a specimen from the left axillary lymph node showed metastatic cells from the squamous cell carcinoma of the
esophagus (×100 magnification)
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Consent
Written informed consent was obtained from the patient
for publication of this case report and the accompanying
images. A copy of the written consent is available for
review from the Editor-in-Chief of this journal.
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